XOMA Royalty Corp(XOMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 25.57 | EPS (ttm) | 1.57 | Insider Own | 0.29% | Shs Outstand | 17.7M | Perf Week | - |
| Market Cap | 0.71B | Forward P/E | - | EPS next Y | -106.1% | Insider Trans | - | Shs Float | 17.6M | Perf Month | -4.24% |
| Enterprise Value | 0.76B | PEG | - | EPS next Q | 0.18 | Inst Own | 42.16% | Short Float | 5.19% | Perf Quarter | 2.03% |
| Income | 0.02B | P/S | 14.63 | EPS this Y | -46.22% | Inst Trans | - | Short Ratio | 2.73 | Perf Half Y | 47.3% |
| Sales | 0.05B | P/B | 5.15 | EPS next 5Y | - | ROA | 10.55% | Short Interest | 0.91M | Perf YTD | 51.07% |
| Book/sh | 7.79 | P/C | 7.48 | EPS past 3/5Y | - 13.2% | ROE | 25.88% | 52W High | -11.17% ($45.22) | Perf Year | 48.01% |
| Cash/sh | 5.37 | P/FCF | 107.12 | Sales past 3/5Y | 105.3% 12.16% | ROIC | 11.55% | 52W Low | 80.22% ($22.29) | Perf 3Y | 135.74% |
| Dividend Est. | - | EV/EBITDA | 91.68 | EPS Y/Y TTM | 249.73% | Gross Margin | 93.16% | Volatility(W/M) | 3.85% 1.79% | Perf 5Y | 22.32% |
| Dividend TTM | - | EV/Sales | 15.65 | Sales Y/Y TTM | 13.16% | Oper. Margin | 10.25% | ATR (14) | 0.91 | Perf 10Y | 292.29% |
| Dividend Ex-Date | - | Quick Ratio | 3.59 | EPS Q/Q | 207.83% | Profit Margin | 41.08% | RSI (14) | 34.34 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | -22.59% | SMA20 | -5.68% ($42.59) | Beta | 0.88 | Target Price | $39 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/04/30 | SMA50 | -4.49% ($42.06) | Rel Volume | 0 | Prev Close | $40.17 |
| Employees | 14 | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | 30.51% 0.26% | SMA200 | 19.2% ($33.7) | Avg Volume(3M) | 0.34M | Price | $40.17 |
| IPO | 1986/6/6 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Company
XOMA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 XOMA Royalty is a biotech royalty aggregator that builds its portfolio by acquiring the royalty economic rights of drug candidates. It diversifies its investments across more than 100 assets, ranging from early-stage partner programs to fully commercialized therapeutics, and operates as a US-listed company with a business model that secures royalty and milestone revenue from its external partners' sales without directly developing drugs itself.
Over the past 1 year, on the higher side
11% below its 1-year high.
XOMA makes money exceptionally well
10.25% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -46.2% this year.
Tap to view numbers
The price looks about right
Trading at 25.6 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +135.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 42.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EVNT 0.01%
QQQS 0.01%
SBAR 0.01%
FOXY 0.01%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $710M.
XOMA $710M PER 25.6
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is XOMA?
XOMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XOMA?
The market cap of XOMA is approximately $710M, ranking 2,896 within its sector.
What is the P/E ratio of XOMA?
XOMA has a P/E ratio of approximately 25.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for XOMA?
XOMA has recorded a 52-week high of $45.22 and a low of $22.29.
